Chugai receives Orphan Drug designation for TECENTRIQ in SCLC
Chugai Pharm announced that humanized anti-PD-L1 monoclonal antibody TECENTRIQ® Intravenous Infusion 1200 mg [atezolizumab (genetical recombination)], and ROS1/TRK inhibitor entrectinib which is under development, received orphan drug designation by the Ministry of Health for treatment of SCLC.
December 06, 2018